tbuckley/cabot-search huggingface dataset:
FRI0208 Metabolic Syndrome in Spondyloarthritis. Prevalence and Associated Factors:
Authors: E. Alonso Blanco-Morales, J. Bravo-Ferrer, R. Rey, C. Bejerano, C. Fernández, N. Oreiro, M. Silva, A. Raga, G. Graña, B. De Aspe, M. Acasuso, F. De Toro, F. Blanco, J. Pinto
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> It has been described a higher prevalence of metabolic syndrome (MetS) in patients with spondyloarthitis (SpA), particularly in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). <h3>Objectives</h3> To describe the prevalence of MetS in SpA patients identifying associated factors and to make a comparison between patients with AS and PsA. <h3>Methods</h3> Observational and retrospective study of 410 SpA patients (188 AS according to modified New York criteria and 222 PsA according to CASPAR criteria) belonging to our follow-up cohort (2004-2014) of northwest of Spain. Demographic, clinical and laboratory data were collected corresponding to baseline visit. MetS was defined according to Adult Treatment Panel III (ATPIII) criteria. Qualitative variables were analyzed using Chi-square/Fisher test and for quantitative variables we used Student t/U Mann Whitney test. Statistical analysis was performed by SPSS 21.0 program. It was considered p&lt;0.05 as significant. <h3>Results</h3> Of the 410 patients, 68.3%, 280 were men (78% in AS and 60% in PsA, p&lt;0.001), the mean age was 50 (±14) years without differences between AS and PsA. We could determine the prevalence of MetS in 287 patients; 37% (107) SpA patients fulfilled ATPIII criteria (47% in PsA versus 24% in AS, p&lt;0.001). The percentages of each item considered in ATP III criteria are exposed in table 1. We observed differences in high levels of blood glucose (32% in PsA and 16% in AS, p&lt;0.001) and high blood pressure (72.2% in PsA and 61.7% in AS, p 0.035). MetS was related with male sex, high age and body surface mass (BMI), hyperuricemia and peripheral forms in the overall sample (p&lt;0.05). In AS MetS was related with higher BASDAI and higher tragus-wall distance. Introducing significant and clinically relevant variables in the multivariate analysis, MetS was related with sex male (OR 4.9, CI 95% 1.85-12.79, p 0.001), higher BMI (OR 1.2 CI 95% 1.11-1.30 p&lt;0.001) and PsA diagnosis (OR 2.7 CI 95% 1.12-6.51 p 0.027). <h3>Conclusions</h3> We demonstrate an elevated prevalence of MetS in SpA patients; that is higher in PsA than in AS patients. These results highlight the importance of detection and early treatment of cardiovascular risk factors in SpA patients. <h3>Disclosure of Interest</h3> None declared
Association of Primary Sclerosing Cholangitis with HLA-DRw52a
Authors: Ernest J. Prochazka, Paul I. Terasaki, Min Sik Park, Leonard I. Goldstein, Ronald W. Busuttil
Journal: New England Journal of Medicine (1990)

We sought to determine whether there are specific HLA haplotypes in patients with either primary sclerosing cholangitis or primary biliary cirrhosis.
Vagus Nerve Stimulation for the Treatment of Heart Failure
Authors: Michael R. Gold, Dirk J. Van Veldhuisen, Paul J. Hauptman, Martin Borggrefe, Spencer H. Kubo, Randy A. Lieberman, Goran Milasinovic, Brett J. Berman, Sanja Djordjevic, Suresh Neelagaru, Peter J. Schwartz, Randall C. Starling, Douglas L. Mann
Journal: Journal of the American College of Cardiology (2016)
Cholestyramine Therapy in Intrahepatic Biliary Atresia
Authors: Fredrik I. Lottsfeldt, William Krivit, J Joseph B. Aust, James B. Carey
Journal: New England Journal of Medicine (1963)

CHOLESTYRAMINE has been shown to relieve pruritus in adults with various forms of partially obstructive liver disease1 , 2 through reduction of serum bile acids. The effect of this resin on an infant with intrahepatic biliary atresia has been studied for two and a half years. A reduction of serum bile acids and serum bilirubin has been repeatedly observed after administration of cholestyramine.Materials and MethodsCholestyramine,∥ a chloride salt of a strongly basic polystyrene anion-exchange resin, containing quaternary ammonium groups, was given in powder form, mixed with applesauce or other fruit. Total daily amount varied between 6.7 and 10.0 gm. Serum . . .
How Much of a Problem Is Peanut in Ground Cumin for Individuals with Peanut Allergy?
Authors: Rebekah L. Sayers, Lee Gethings, Antonietta Wallace, Aida Semic-Jusufgic, Angela Simpson, Perdita Barran, John Gilbert, Hamide Senyuva, Adrian Rodgers, Mike Bromley, Michael Walker, Helen Brown, E.N. Clare Mills
Journal: Journal of Allergy and Clinical Immunology (2016)
Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection
Authors: Peter A. Selwyn, Philip Alcabes, Diana Hartel, Donna Buono, Ellie E. Schoenbaum, Robert S. Klein, Katherine Davenny, Gerald H. Friedland
Journal: New England Journal of Medicine (1992)

To examine the clinical course of human immunodeficiency virus (HIV) infection in injection-drug users, we conducted a prospective study of a cohort of patients in a methadone-treatment program in New York City from July 1985 through December 1990. The patients underwent standardized evaluations at base line and semiannually thereafter and received on-site primary medical care. Rates of progression to the acquired immunodeficiency syndrome (AIDS) and major outcomes before the development of AIDS were examined by univariate analyses; the risk of AIDS was also assessed by product-limit survival analysis and proportional-hazards regression.
Oral Pilocarpine for Post-Irradiation Xerostomia in Patients with Head and Neck Cancer
Authors: Jonas T. Johnson, Gerald A. Ferretti, W. James Nethery, Ingrid H. Valdez, Philip C. Fox, David Ng, Charles C. Muscoplat, Susan C. Gallagher
Journal: New England Journal of Medicine (1993)

We evaluated pilocarpine hydrochloride for the treatment of radiation-induced xerostomia, a common complication of irradiation of the head and neck. A prospective, randomized, double-blind, placebo-controlled trial was undertaken to test the safety and efficacy of pilocarpine, particularly in reversing the decrease in the production of saliva and other manifestations of xerostomia. Patients received either placebo or pilocarpine (5 mg or 10 mg orally three times a day) for 12 weeks and were evaluated at base line and every 4 weeks.
Uneasy Alliance — Clinical Investigators and the Pharmaceutical Industry
Authors: Thomas Bodenheimer
Journal: New England Journal of Medicine (2000)

Clinical practice is changing rapidly. New cardiovascular drugs, antiinflammatory drugs, cancer chemotherapy, and other pharmacologic weapons are being added to physicians' therapeutic armamentarium virtually daily. Most clinical studies that bring new drugs from bench to bedside are financed by pharmaceutical companies. Many of these drug trials are rigorously designed, employing the skills of outstanding clinical researchers at leading academic institutions.But academic medical centers are no longer the sole citadels of clinical research. The past 10 years have seen the spectacular growth of a new research model. Commercially oriented networks of contract-research organizations (CROs) and site-management organizations (SMOs) have altered . . .
Angiocardiography in the Diagnosis of Saccular Aneurysm of the Abdominal Aorta
Authors: Israel Steinberg, Nathaniel Finby
Journal: New England Journal of Medicine (1956)

RECENTLY, Vaughan and his associates1 described the successful excision under emergency conditions of an aneurysm of the abdominal aorta that was explored with the preoperative diagnosis of a paraspinal tumor. In the discussion of the case, the authors stated that angiocardiography, if it had been done, would have disclosed the aneurysm, and more successful preparation could then have been made for definitive surgery. This proved to be the situation in the case reported below. Once angiocardiography had established the diagnosis of a saccular aneurysm of the aorta eroding the bodies of the twelfth dorsal and first lumbar vertebras, surgical excision . . .
Differing age patterns in chronic myeloid leukemia by racial ethnic group.
Authors: A. M. Mendizabal, W. F. Anderson, P. Garcia-Gonzalez, P. H. Levine
Journal: Journal of Clinical Oncology (2010)

1577 Background: The Glivec International Patient Assistance Program (GIPAP) was initiated in 2001 to supply doses of imatinib free of cost to CML patients in developing countries. In reviewing the pattern of CML among the 32,032 patients treated from 90 countries, it was apparent that the age of diagnosis was occurring at a younger age (median: 38 years [y] with 95% < 64y) compared to that of the United States (US) (median: 66y). A descriptive epidemiological study was warranted to describe the age patterns of CML. Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) 17 Registries (1973-2006) and the 72 registries published in Cancer Incidence in Five Continents (CI5) (1958-1997) were analyzed. Results: 18,923 cases of CML were reported in SEER with 25% < 49y. 57% were male and 84% were white (9% black, 7% other). Age frequency distributions at diagnosis showed differences based by race; whites exhibited a peak frequency near 75y, whereas blacks had a bimodal age distribution (40 y and 70 y). Other races exhibit a shift in the age distribution to younger patients. The age-adjusted rate per 100,000 was 1.67 with a higher rate in males compared to females (2.19 vs. 1.29). Incidence rate curves and age-period-cohort (APC) fitted age-at- onset curves were similar for males versus females. Rates were similar for white and black (1.65 vs 1.68). However, an age-specific incidence rate crossover was observed between black and white cases with rates higher among blacks < 50 y and rates higher among whites > 70 y. Data from CI5 show a bimodal distribution (35-44 y and 60-74 y). Conclusions: Bimodal age distributions at diagnosis by race and ethnicity have emerged from this analysis of three different datasets. The GIPAP cohort suggested a younger age at diagnosis. The differential age pattern was supported by the SEER analysis suggesting an earlier age at onset (30-40 y) and a later age of onset (65-75 y). Crossover in incidence rates between black and white was consistent. A similar bimodal distribution among CI5 was also concluded. To our knowledge, this is the first report of bimodal CML, suggesting two distinct populations in an otherwise homogeneous disease. Additional analytical studies are needed to determine the source of this heterogeneity. No significant financial relationships to disclose.
Acute Mountain Sickness
Authors: Inder Singh, P. K. Khanna, M. C. Srivastava, Madan Lal, Sujoy B. Roy, C. S. V. Subramanyam
Journal: New England Journal of Medicine (1969)

Observations on acute mountain sickness occurring between 11,000 and 18,000 feet, in 1925 men, 18, to 53 years old, showed no direct relation between altitude and severity of illness; mild, moderate and severe cases occurred at all altitudes. A time lag of six to 96 hours between arrival and onset of symptoms ruled out any direct relation between hypoxia and acute mountain sickness. During this period there was clinical evidence of respiratory dysfunction with slow, irregular or Cheyne—Stokes breathing, pulmonary congestion and antidiuresis. In one biopsy and two autopsy studies there was evidence of cerebral edema. Diuresis induced with furosemide provided effective routine therapy. Morphine and betamethasone were used as additional aids in severe cases. Clinical features of acute mountain sickness were ascribed to hypoxia, pulmonary congestion, increased cerebral blood flow, increased cerebrospinal-fluid pressure and cerebral edema.
Antigenic Heterogeneity of Skin Tumors of Nonmelanocyte Origin: Analysis With Monoclonal Antibodies to Tumor-Associated Antigens and to Histocompatibility Antigens&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: P G Natali, M Viora, M R Nicotra, P Giacomini, A Bigotti, S Ferrone
Journal: JNCI Journal of the National Cancer Institute (1983)

Surgically removed benign and malignant human skin lesions of nonmelanocyte origin have been tested with monoclonal antibodies to la antigens, to the HLA-A,B antigenic molecular complex, and to melanoma-associated antigen(s) (MAA). MAA include a high-molecular-weight (HMW) MAA, a 115,000-molecular-weight MAA, a 94,000-molecular-weight MAA, and a cytoplasmic MAA. Indirect immunofluorescence was used as the assay system because of the limited amount of tissue available. When the amount of tissue available was sufficient, double determinant immunoassays (DDIA) were used to quantitate the level of the HMW MAA and of the cytoplasmic MAA. The results of the DDIA were in agreement with those of indirect immunofluorescence in more than 75% of the cases. Malignant skin tumors of various histiotypes displayed three types of changes: 1) appearance of la antigens and cytoplasmic MAA, 2) increase in the level of the HMW MAA, of a 115,000- and a 100,000-molecular-weight MAA, and 3) reduction in the level of HLA-A,B antigens and beta 2-microglobulin. A significant heterogeneity was found in the antigenic profile among various lesions of a given histiotype as well as among tumor cells within a given lesion.
Demonstration of an Antigen Common to Several Varieties of Neoplasia
Authors: Paul Lo Gerfo, John Krupey, Hans J. Hansen
Journal: New England Journal of Medicine (1971)

Abstract The serum or plasma of 674 patients was studied by means of a radioimmunoassay that detects on carcinoembryonic antigen (CEA) an antigenic site exposed at low ionic strength. Serum specimens from 11 of 299 patients hospitalized for various illnesses other than neoplastic disease had elevated levels of antigen. Subsequently, two of these patients were found to have previously undetected entodermally derived adenocarcinoma. Elevated levels of CEA were observed in serum specimens from 87 of 101 patients with known colonic adenocarcinoma, 30 of 45 patients with breast carcinoma, 26 of 35 patients with lung carcinoma and 20 of 51 patients with prostatic carcinoma. Since serum from patients with both entodermally and nonentodermally-derived carcinoma had elevated levels of CEA an antigenic site common to several tumors appears to exist on CEA.
Association of Respiratory Viral Infections with Pulmonary Deterioration in Patients with Cystic Fibrosis
Authors: Elaine E.L. Wang, Charles G. Prober, Barbara Manson, Mary Corey, Henry Levison
Journal: New England Journal of Medicine (1984)

In a two-year prospective study, we examined the effect of respiratory viral infections on pulmonary function in 49 patients with cystic fibrosis (mean age, 13.7 years). Nineteen normal siblings (mean age, 14) served as controls. Subjects were assessed quarterly and at the time of any respiratory illness. Each assessment included nasal washes for viral isolation and blood drawing for respiratory viral serologic studies. Pulmonary-function tests were performed at least twice yearly. Respiratory illnesses were reported significantly more often in the patients (3.7 per year) than in the normal siblings (1.7 per year), although the frequency of proved viral infections (1.67 per year) was identical. In the patients with cystic fibrosis significant correlations (P less than 0.0001) were found between the annual incidence of viral infections and every measure of disease progression in the two-year period, including the rate of decline of the Shwachman score (r = 0.71), the percentage of ideal weight for height (r = 0.80), the forced vital capacity (r = 0.85), the forced expiratory volume in the first second (r = 0.84), the forced midexpiratory flow rate (r = 0.68), and the frequency (r = 0.53) and duration (r = 0.84) of hospitalizations for respiratory exacerbations. We conclude that frequency of viral respiratory infections is closely associated with pulmonary deterioration in patients with cystic fibrosis.
PTH-301 Emergency versus elective malignant colorectal resections: a single centre experience
Authors: M Gok, KI Malik, A Jeff, UA Khan
Journal: Gut (2015)

<h3>Introduction</h3> Colorectal Cancer (CRC) is the 3<sup>rd</sup>most common and 2<sup>nd</sup>most lethal malignancy in men and women in the UK. CRC presents as a surgical emergency in &lt;30% of cases; obstruction, perforation, abdominal pain, haemorrhage or sepsis. Emergency CRC has been associated with high post-operative morbidity and mortality. The aim of the study is to assess emergency CRC resections at a single centre. <h3>Method</h3> This is a retrospective study carried out since January 2008 at Macclesfield District General Hospital. Patient factors, histopathology and surgical outcomes were evaluated for all emergency malignant colorectal resections. A cohort of elective malignant colorectal resections carried out since 2008 were recruited as controls. <h3>Results</h3> See Table 1 <h3>Conclusion</h3> Colorectal malignancy is more predominant in males, however emergency presentation was less predictable. Prolonged operative time in elective cases is attributed to use of laparoscopy. Emergency colorectal patients were generally ill patients (ASA 3) with sepsis. The greater LB specimen reflects more diseased (less viable LB due to obstruction) LB resection in the emergency cases. Consequently the survival was poorer in emergency colorectal resections. This study supports the bowel screening initiatives to detect early colorectal cancers. <h3>Disclosure of interest</h3> None Declared.
SAT0262 Should Imaging of the SI Joints be Repeated After 1 Year? Impact on the Classification of Patients According to the ASAS Axial SPA Criteria
Authors: P. Bakker, M. van Lunteren, Z. Ez-Zaitouni, R. van den Berg, M. de Hooge, I. Berg, R. Landewé, M. van Oosterhout, R. Ramonda, T. Huizinga, M. Reijnierse, F. van Gaalen, D. van der Heijde
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> It is known that in axial spondyloarthritis (axSpA) inflammatory lesions on MRI of the SI joints (MRI-SI) can change over time. The usefulness of repeating imaging in the diagnostic process is unclear. <h3>Objectives</h3> To investigate how patients with short-term chronic back pain are classified by the ASAS axSpA- criteria at baseline and after 1-year follow-up, focussing on the role of imaging. <h3>Methods</h3> Patients in the SPACE-cohort (back pain: ≥3 months, ≤2 years, onset &lt;45 years) with (suspicion of) axSpA underwent MRI and X-rays of the SI-joints at baseline and 1-year follow-up. Patients with complete MRI- and X-SI data at both timepoints were included in the analysis (n=185). MRI-SI and X-SI were scored by 3 different well-calibrated readers independently according to the ASAS-definition for a positive MRI and the mNY-criteria, blinded for patient characteristics and time sequence. Fulfillment of ASAS-MRI or mNY-criteria was considered positive if 2/3 readers agreed. At each timepoint, patients were classified according the ASAS axSpA-criteria and grouped in the different arms (imaging arm: mNY+/- or MRI+/-; clinical arm, fulfilment of both arms and possible axSpA). At year one, in contrary to the normal application of the criteria, where a positive feature remains positive:we grouped patients according to the finding at that timepoint, ignoring previous imaging findings. <h3>Results</h3> At baseline, 92/185 patients (49.7%) fulfilled the ASAS criteria (clinical arm: 53; imaging arm: 15, both arms: 24) (table). At 1 year, 14 additional patients fulfilled the criteria (8 clinical arm; 5 imaging arm only; 1 both arms). After 1 year, in 12 patients MRI-SI became positive. As a result, 14/93 (15.1%) of the no SpA or possible SpA patients at baseline could be classified additionally as axSpA because of additional SpA features (n=8), a positive MRI (n=4) or sacroiliitis according to the mNY-criteria (n=2), On the other hand, MRI-SI became negative after 1 year in 12 other patients. Of these patients, 10 still fulfilled the ASAS criteria (clinical arm (n=7) or both arms (n=3)). Only 4 patients (classified as axSpA at baseline) would be missed if imaging would have been performed only at 1 year (due to negative MRI or x-ray findings). <h3>Conclusions</h3> In our cohort, a signifcant number of patients with no SpA or possible SpA at baseline developed (additional) SpA features leading to fulfilment of axSpA criteria at year one. However, our data show the robustness of the axSpA criteria and there is only limited evidence for repeating imaging after one year. <h3>Disclosure of Interest</h3> None declared
Heterotypic Antibody Response after Feeding of Monovalent Attenuated Live Poliovaccine
Authors: Asaria Ashkenazi, Joseph L. Melnick
Journal: New England Journal of Medicine (1962)

THE goal of vaccination against poliomyelitis is the production of enduring immunity by a single administration of vaccine. With killed vaccine of the presently available potency this is not possible. With live vaccine there are a number of reports1 2 3 4 5 6 showing conversions for two or three serotypes after a single feeding of trivalent vaccine. It has usually been assumed that such multiple conversions are indicative of multiple infections by the virus types in the vaccine. The extent to which such multiple conversions are due to heterotypic responses to infection by only a single type in the vaccine has not been adequately . . .
A phase I dose finding study of E7080 in patients (pts) with advanced malignancies
Authors: H. Glen, D. Boss, T. R. Evans, M. Roelvink, J. M. Saro, P. Bezodis, W. Copalu, A. Das, G. Crosswell, J. H. Schellens
Journal: Journal of Clinical Oncology (2007)

14073 Background: E7080 is a potent inhibitor of the split-kinase family of transmembrane growth factor receptors including Flt-1 and KDR. In addition, E7080 also potently inhibits FGFR1 and PDGFRβ tyrosine kinase activities. In an in vitro angiogenic model, E7080 inhibited VEGF-driven umbilical vein endothelial cell (HUVEC) proliferation and tube formation. Using H460 and Colo205 mouse xenograft models, E7080 significantly inhibited tumor growth at doses from 1 to 100 mg/kg. Methods: A Phase I and pharmacologic study was conducted to determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of E7080 in pts with advanced malignancies. Eligible pts with adequate hematologic, renal and hepatic function, and with tumors refractory to standard therapies, were treated with E7080 administered orally on a once daily continuous dose schedule in cycles of 4 weeks. Dose escalation was performed according to an accelerated design of 100% dose increases in subsequent cohorts until the first patient experienced ≥ CTC grade 2 toxicity. Results: As of November 17th, 2006, 37 pts with documented progressive disease (PD) have been treated at the following dose levels: 0.2 mg/d, 0.4 mg/d, 0.8 mg/d, 1.6 mg/d, 3.2 mg/d, 6.4 mg/d, 12.5 mg/d and 16 mg/d. Median number of cycles was 1 (0–11). Median age = 60 years (25–84), 20 pts were male, 17 were female. 37 pts were evaluable for toxicity. 1 patient experienced grade 3 hypertension (DLT) in the 16 mg/d cohort, other related toxicities ≥ grade 2 include hemorrhage and thrombosis (n=1), tachycardia (n=1), febrile neutropenia (n=1), proteinuria (n=1), thrombocytopenia (n=1) and hypertension (n=1). MTD has not been reached and this study is continuing to recruit. 24 pts were evaluable for efficacy, 3 are too early to evaluate. 1 patient had a partial response (high grade sarcoma) after 2 cycles, and 15 pts experienced stable disease from 2+ to 11 months, and 11 pts continue on therapy. Pharmacokinetic (PK) studies: preliminary data suggest that the PK is linear over the range 0.2 mg/d to 12.5 mg/d. Conclusions: E7080 is safe and well tolerated at doses acheived so far and has shown promising first signs of anti-cancer activity associated with potent activity in pre-clinical models. Clinical and PK data from subsequent doses and follow- up will be presented. No significant financial relationships to disclose.